NCT01616485

Study to Evaluate Hemodynamic Response to to a Sublingual Dose of Glyceryl Trinitrate in Subjects Receiving TA-1790, Sildenafil Citrate, and Placebo

A Double-blind, Randomized, Crossover Evaluation of the Hemodynamic Response to Sublingual Glyceryl Trinitrate in Patients Receiving TA-1790, Sildenafil, and Placebo

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 106 (actual)
• Sponsor: VIVUS LLC · Industry
• Sex: Male
• Age: 30 Years – 60 Years
• Healthy volunteers: Accepted

Summary

The objective of this study is to evaluate the hemodynamic response to a sublingual dose of glyceryl trinitrate in subjects receiving oral TA-1790, sildenafil citrate, and placebo.

Conditions

• Erectile Dysfunction

Interventions

Type	Name	Description
DRUG	TA-1790	2 TA-1790 100 mg capsules
DRUG	Sildenafil citrate	2 sildenafil citrate 50 mg capsules
DRUG	Placebo	2 placebo capsules for TA-1790 100 mg capsules
DRUG	Nitrostat	glyceryl trinitrate tablet, USP 0.4 mg

Timeline

• Start date: 2004-03-01
• Primary completion: 2004-05-01
• Completion: 2004-05-01
• First posted: 2012-06-11
• Last updated: 2012-06-14

Locations

1 site across 1 country: United States